Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-11-01
2005-11-01
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S047000, C544S048000, C544S049000
Reexamination Certificate
active
06960579
ABSTRACT:
Compounds with 5HT7receptor affinity (some of which are novel) useful for lowering IOP, improving blood flow to the optic nerve head and the retina, providing neuroprotection, and treating retinal diseases are disclosed. The Compounds are also useful for treating sleep disorders, depression, and other psychiatric disorders, such as, schizophrenia, anxiety, obsessive compulsive disorder, circadian rhythm disorders, and centrally and peripherally mediated hypertension. Compositions and methods for their use are also disclosed.
REFERENCES:
patent: 3303189 (1967-02-01), Loev
patent: 5011846 (1991-04-01), Gittos et al.
patent: 5106855 (1992-04-01), McLees
patent: 5153192 (1992-10-01), Dean et al.
patent: 5290781 (1994-03-01), Espino et al.
patent: 5344929 (1994-09-01), Dean et al.
patent: 5470973 (1995-11-01), Hoff
patent: 5538966 (1996-07-01), May et al.
patent: 5538974 (1996-07-01), Ogawa et al.
patent: 5652272 (1997-07-01), Ogawa et al.
patent: 5693654 (1997-12-01), Birch
patent: 5874429 (1999-02-01), Mizuno et al.
patent: 5880134 (1999-03-01), Cohen et al.
patent: 6271223 (2001-08-01), Mizuno et al.
patent: 0522226 (1993-01-01), None
patent: 0738513 (1996-10-01), None
patent: 0771563 (1997-05-01), None
patent: 9220338 (1992-11-01), None
patent: 9717345 (1997-05-01), None
patent: 9729097 (1997-08-01), None
patent: 9748681 (1997-12-01), None
patent: 9749695 (1997-12-01), None
patent: 9800400 (1998-01-01), None
Sianesi et al. (DE 2022694) 1970. Abstract.
Sianesi et al. (J. Med. Chem (1973), 16(10), 1133-7)). Abstract.
Dean et al. (US 5,153,192). 1991. Abstract.
Mizuno et al. (WO 95/18117). 1995. Abstract.
May et al. (WO 95/19981). 1995 Abstract.
Masaki et al. (WO 95/26959). 1995. Abstract.
US 5538966 (Abstract) 1996.
Zifa and Fillion, “5-Hydroxytryptamine Receptors,”Pharmacol. Rev., vol. 44(3):401-458, 1992.
Hoyer et al., “VII. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin),”Pharmacol. Rev., vol. 46(2):157-203, 1994.
Martin et al., “The structure and signalling properties of 5-HT receptors: an endless diversity,”Trends Pharmacol. Sci., vol. 19:2-4, 1998.
Eglen et al., “The 5-HT7Receptor: Orphan Found,”Trend Pharmacol. Sci., vol. 18:104-107, 1997.
Heidmann et al.,“four 5-Hydroxytryplamine7(5-HT7) Receptor Isoforms in Human and Rat Produced by Alternative Splicing: Species Differences Due to Altered Intron-Exon Organization,”J. Neurochem., vol. 68(4):1372-1381, 1997.
Chiou, et al., “Effects of Antiglaucoma Drugs on Ocular Blood Flow in Hypertensive Rabbits,”J. Ocular Pharmacol., vol. 9(1):13-24, 1993.
Martin et al., “Serotonin in Human Aqueous Humor,”Ophthalmol., vol. 95(9):1221-1226, 1988.
Mallorga and Sugrue, “Characterization of serotonin receptors in the iris + ciliary body of the albino rabbit,”Curr. Eye Res., vol. 6(3):527-532, 1987.
Chidlow et al., “Characteristics of [3H]5-Hydroxytryptamine Binding to Iris—Cilary Body Tissue of the Rabbit,”Invest. Ophthalmol. Vis. Sci., vol. 36(11):2238-2245, 1995.
Tobin and Osborne, “Evidence for the Presence of Serotonin Receptors Negatively Coupled to Adenylate Cyclase in the Rabbit Iris-Ciliary Body,”J. Neurochem., vol. 53(3):686-601, 1989.
Barnet and Osborne, “The Presence of Serotonin (5-HT1) Receptors Negatively Coupled to Adenylate Cyclase in Rabbit and Human Iris-Ciliary Processes,”Exp. Eye Res., vol. 57:209-216, 1993.
Osborne and Chidlow, “Do Beta-Adrenoceptors and Serotonin 5-HT1AReceptors Have Similar Functions in the Control of Intraocular Pressure in the Rabbit?,”Ophthalmologica, vol. 210:308-314, 1996.
Meyer-Bothling et al., “Topical Application of Serotonin or the 5-HT1-Agonist 5-CT Intraocular Pressure in Rabbits,”Invest. Ophthalmol. Vis. Sci., vol. 34(10):3035-3042, 1993.
Krootila et al., “Effect of Serotonin and Its Antagonist (Ketanserin) on Intraocular Pressure in the Rabbit,”J. Ocular Pharmacol., vol. 3(4):279-290, 1987.
Costagliola et al., “Fluoxetine Oral Administration Increases Intraocular Pressure,”Br. J. Ophthalmol., vol. 80:678, 1996.
Ahmad, “Fluoxetine and glaucoma,”Annuals of Pharmacother., vol. 25:436, 1992.
Wang, et al., “Effect of 5-methylurapidil, an α1a-adrenergic antagonist and 5-hydroxytryptamine1aagonist, on aqueous humor dynamics in monkeys and rabbits,”Curr. Eye Res., vol. 16:769-775, 1997.
Wang, et al., “Effect ofp-MPPI Hydrochloride (p-MPPI) Applied Before 5-methylurapidil (5-MU) on Intraocular Pressure,”Invest. Ophthal. Vis. Sci., vol. 39(Suppl):2236-S488, 1998.
Chang, et al., “Mechanism of the Ocular Hypotensive Action of Ketanserin,”J. Ocular Pharmacol., vol. 1(2):137-147, 1985.
Costagliola, et al., “Effect of Oral Ketanserin Administration on Intraocular Pressure in Glaucomatous Patients,”Ex. Eye Res., vol. 52:507-510, 1991.
Mano, et al., “The Effect of Anplag (Sarpogrelate HCL), New Selective 5-HT2Antagonist on Intraocular. Pressure in Rabbits,”Invest. Ophthal. Vis. Sci., vol. 36(Suppl):3322-309, 1995.
Takenaka, et al., “the Effect of The Effect of Anplag (Sarpogrelate HCL), Novel Selective 5-HT2Antagonist on Intraocular Pressure in Glauoma Patients,”Invest Ophthal. Vis. Sci., vol. 36(Suppl):3390-377, 1995.
Zinnes, et al., “1,2-Benzohtiazines. III. The Preparation of 2H-1,2-Benzothiazin-4(3H)-one 1,1-Dioxide by the Acid-Catalyzed Deacetylation of β-Diketone,”J. Org. Chem.vol. 31:162-165, 1966.
Jae, et al., “Pyrrolidine-3-carboxylic Acids as Endothelin Antagonists. 2. sulfonamide BasedETA/ETBMixed Antagonists,”J. Med. Chem.vol. 40:3217-3227, 1997.
Chen Hwang-Hsing
Dean Thomas R.
May Jesse A.
Sharif Najam A.
Alcon Manufacturing Ltd.
Copeland Barry L.
Kifle Bruck
Ryan Patrick M.
Yeager Sally S.
LandOfFree
Serotonergic 5HT 7 receptor compounds for treating ocular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Serotonergic 5HT 7 receptor compounds for treating ocular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Serotonergic 5HT 7 receptor compounds for treating ocular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3472598